Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Transitioning to Biosimilar Rituximab (DRL_RI) in RA
NCT04268771Phase 3Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Apr 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in rheumatoid arthritis (RA), sponsored by Dr. Reddy's Laboratories. Started Apr 2020; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04268771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04268771.